Dare Bioscience (Dare Bioscience) Accounts Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Dare Bioscience's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Dare Bioscience's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Dare Bioscience's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.16.

Dare Bioscience Accounts Receivable Historical Data

The historical data trend for Dare Bioscience's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Accounts Receivable Chart

Dare Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Dare Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Dare Bioscience Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Dare Bioscience Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Dare Bioscience's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	1.808	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Dare Bioscience's accounts receivable are only considered to be worth 75% of book value:

Dare Bioscience's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(10.476	+	0.75 * 0	+	0.5 * 0	-	26.33
-	0	-	0)	/	99.9739
=	-0.16

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Dare Bioscience Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Dare Bioscience (Dare Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122

Website

https://www.darebioscience.com

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Executives

Sophia Nnenna Ononye-onyia	director	1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson	director, officer: Chef Executive Officer	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair	officer: Chief Strategy Officer	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley	director	3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz	director	1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman	director	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert	officer: Chief Financial Officer	C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof	officer: SVP, Chief Scientific Officer	C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz	officer: SVP, Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle	director	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal	officer: VP, General Counsel	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill	officer: Principal Accounting Officer	15 GREENBRIAR CIRCLE, ANDOVER MA 01810